GlassScriptPhysician profile
Hassan Taki
NPI 1114911807
$7,841.86
in general payments reported to CMS, 2019-2025
22 companies · $599 in 2025
The $599 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $408 · 2021: $1,723 · 2022: $1,701 · 2023: $913 · 2024: $1,514 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,003 · Education: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.12 |
| Education | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,009.21 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Pfizer INC. | $1,584.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,419.56 | 2019-2024 | Airsupra, Tezspire |
| Biohaven Pharmaceuticals, INC. | $598.59 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $426.18 | 2021-2023 | Cuvitru |
| Phathom Pharmaceuticals, INC. | $336.12 | 2024-2025 | Voquezna |
| Optinose US, INC. | $240.58 | 2022-2025 | |
| Abbvie INC. | $208.36 | 2021-2023 | Ubrelvy, Qulipta |
| Biohaven Pharmaceutical Holding Company LTD. | $178.56 | 2022 | |
| Axsome Therapeutics, INC. | $146.45 | 2025 | Symbravo |
| Mylan Specialty L.P. | $139.61 | 2019 | |
| Amgen INC. | $136.02 | 2022 | |
| Genentech USA, INC. | $132.30 | 2024 | Xolair |
| Genzyme Corporation | $96.17 | 2019 | |
| Csl Behring | $49.02 | 2019-2024 | Hizentra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $32.45 | 2020-2021 | |
| Octapharma USA, INC. | $24.31 | 2024 | Octagam Immune Globulin (Human) |
| Lundbeck LLC | $21.82 | 2024 | Vyepti |
| Mallinckrodt Hospital Products INC. | $16.73 | 2021 | |
| Hospira, INC. | $16.20 | 2024-2025 | |
| Adma Biomanufacturing LLC | $14.76 | 2022 | |
| Kaleo, INC. | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Taki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.